Equibles does not estimate personal net worth.
Get an email with a short summary when Emergent BioSolutions Inc. publishes a filing, an earnings call transcript or a press release.
Get EBS alertsJoe Papa is recorded as CEO at Emergent BioSolutions Inc. (EBS), CEO at Bausch Health Companies Inc. (BHC) and CEO at Bausch & Lomb Corp (BLCO). Joe Papa has spoken on 11 earnings calls and 1 other investor event across 3 companies, most recently for Emergent BioSolutions Inc. on November 2, 2026. Those appearances were for Emergent BioSolutions Inc. (EBS), Bausch Health Companies Inc. (BHC) and Bausch & Lomb Corp (BLCO). Emergent BioSolutions Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Bausch Health Companies Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Emergent BioSolutions Inc. includes Daniel J. Abdun-Nabi (CEO, COO and Board Member), Joseph C. Papa (CEO and Board Member), Joseph Papa (CEO and Board Member) and 7 others.
“This afternoon, I will share an update on our multi-year transformation plan, the actions we implemented during the quarter to strengthen the business, and the progress we are making across our diversified medical countermeasures and Nalaxone portfolios.”
“Pleasure to be here today, and thank you very much for your interest an emergency unique company. We have a 26-year history of working with the U.S. government, other governments around the world, to partner with them to create biodefense programs, activities where we help them prepare.”
“Hello, everyone, and thank you for joining us to discuss Emergent's second quarter 2026 financial results. This is Joe Papa, president and CEO of Emergent, and I'm joined today by Rich Lindell, our chief financial officer.”
“I'm joined today by Rich Lindahl, our Chief Financial Officer. Let's turn to slide five. Our aspiration at Emergent is to be the leader in solving public health threats around the world.”
“I'll start with our multi-year transformation plan progress and top-line business results. Rich will walk through the fourth quarter and full-year 2025 financials and provide our 2026 guidance.”
Drug Manufacturers - Specialty & Generic · Healthcare
CEO
Drug Manufacturers - Specialty & Generic · Healthcare
CEO
BLCO
Medical Instruments & Supplies · Healthcare
CEO
